Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C32H40N2O |
Molecular Weight | 468.6728 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1CN[C@H]2C3CCN(CC3)[C@H]2C(C4=CC=CC=C4)C5=CC=CC=C5)C(C)(C)C
InChI
InChIKey=OMPCVMLFFSQFIX-CONSDPRKSA-N
InChI=1S/C32H40N2O/c1-32(2,3)27-15-16-28(35-4)26(21-27)22-33-30-25-17-19-34(20-18-25)31(30)29(23-11-7-5-8-12-23)24-13-9-6-10-14-24/h5-16,21,25,29-31,33H,17-20,22H2,1-4H3/t30-,31-/m0/s1
Molecular Formula | C32H40N2O |
Molecular Weight | 468.6728 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/pro/cerenia.htmlCurator's Comment: Description was created based on several sources, including
http://cerenia.com/
http://www.fda.gov/downloads/AnimalVeterinary/ucm062313.pdf
Sources: https://www.drugs.com/pro/cerenia.html
Curator's Comment: Description was created based on several sources, including
http://cerenia.com/
http://www.fda.gov/downloads/AnimalVeterinary/ucm062313.pdf
Maropitant (trade name Cerenia in the U.S. and other countries), used as maropitant citrate is a neurokinin (NK1) receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007 for use in dogs, and was later approved for use in cats. Maropitant also has anti-nociceptive (analgesic) properties. Maropitant inhibits binding of substance P to NK-1 receptors. Substance P is an emetogen experimentally, and is found endogenously, along with NK-1 receptors, in the emetic center, chemoreceptor trigger zone, and in vagal afferent nerves in the gastrointestinal tract.
CNS Activity
Sources: https://www.drugs.com/pro/cerenia.html
Curator's Comment: Maropitant, a lipophilic compound, crosses the blood-brain barrier http://veterinarymedicine.dvm360.com/maropitants-pharmacokinetics-and-pharmacology
Maropitant is a neurokinin (NK1) receptor antagonist that blocks the pharmacological action of substance P in the central nervous system (CNS).
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q5DUB3 Gene ID: 403815.0 Gene Symbol: TACR1 Target Organism: Canis lupus familiaris (Dog) (Canis familiaris) |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://cerenia.com/ |
Preventing | Cerenia Approved UseCerenia is indicated for the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs. Launch Date2007 |
PubMed
Title | Date | PubMed |
---|---|---|
The neurokinin-1 antagonist activity of maropitant, an antiemetic drug for dogs, in a gerbil model. | 2007 Aug |
|
Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats. | 2008 Jun |
|
Acute pancreatitis attributed to dietary indiscretion in a female mixed breed canine. | 2010 Feb |
|
In vivo assessment of antiemetic drugs and mechanism of lycorine-induced nausea and emesis. | 2011 Dec |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/cerenia.html
Curator's Comment: Can also be injected subcutaneously
http://www.fda.gov/downloads/AnimalVeterinary/ucm062313.pdf
For Prevention of Vomiting Due to Motion Sickness
Administer Cerenia (Maropitant) Tablets orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days. Dogs should be fasted 1 hour prior to administration of Cerenia Tablets. Administer Cerenia Tablets 2 hours prior to travel.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25947563
Maropitant (0.1-10 uM) increased frequency of whole murine intestine contraction, decreased amplitude of contraction and totally inhibited motility index in a concentration-dependent manner.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:25:30 GMT 2023
by
admin
on
Fri Dec 15 16:25:30 GMT 2023
|
Record UNII |
4XE2T9H4DH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 520.1315
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
||
|
WHO-VATC |
QA04AD90
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
||
|
CFR |
21 CFR 522.1315
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
||
|
NCI_THESAURUS |
C267
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4XE2T9H4DH
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
PRIMARY | |||
|
C81500
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
PRIMARY | |||
|
CHEMBL2111099
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
PRIMARY | |||
|
C518176
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
PRIMARY | |||
|
715869
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
PRIMARY | RxNorm | ||
|
147116-67-4
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
PRIMARY | |||
|
300000023688
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
PRIMARY | |||
|
DTXSID1057874
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
PRIMARY | |||
|
204108
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
PRIMARY | |||
|
MAROPITANT
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
PRIMARY | |||
|
m7089
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
PRIMARY | Merck Index | ||
|
4XE2T9H4DH
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
PRIMARY | |||
|
8421
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
PRIMARY | |||
|
DB11427
Created by
admin on Fri Dec 15 16:25:31 GMT 2023 , Edited by admin on Fri Dec 15 16:25:31 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |